title: Novel vaccine prime and selective BCG boost: a new tuberculosis vaccine strategy for infants of HIV-infected mothers.
abstract: Novel tuberculosis vaccination strategies hinge on BCG priming, yet newborn BCG vaccination may cause BCG disease in HIV-infected infants. Viral-vectored or subunit prime vaccine, followed by delayed BCG boost only for HIV-uninfected infants, may be a safe alternative for all newborns, regardless of maternal HIV infection. This approach should be tested using new tuberculosis vaccine candidates. If safety and immunogenicity of a novel vaccine prime is established in infants of HIV-infected mothers, for whom newborn BCG carries unacceptable risk, this strategy might then be compared to conventional BCG prime and viral-vectored or subunit boost, and BCG alone, in HIV-unexposed infants.
authors.forename: Mark
authors.initials: M
authors.lastname: Hatherill
authors.forename: Hassan
authors.initials: H
authors.lastname: Mahomed
authors.forename: Willem
authors.initials: W
authors.lastname: Hanekom
mesh_terms: D001500:BCG Vaccine / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D009035:Mothers; D014376:Tuberculosis / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine